Bbva Compass Bancshares Inc. decreased its position in Johnson & Johnson (NYSE:JNJ) by 1.2% during the second quarter, Holdings Channel reports. The firm owned 77,636 shares of the company’s stock after selling 976 shares during the period. Bbva Compass Bancshares Inc.’s holdings in Johnson & Johnson were worth $9,417,000 at the end of the most recent quarter.
A number of other large investors have also recently added to or reduced their stakes in the company. Stratford Consulting LLC increased its stake in Johnson & Johnson by 0.6% in the second quarter. Stratford Consulting LLC now owns 3,201 shares of the company’s stock worth $388,000 after buying an additional 18 shares during the period. Gateway Advisory LLC increased its stake in Johnson & Johnson by 0.5% in the first quarter. Gateway Advisory LLC now owns 4,215 shares of the company’s stock worth $456,000 after buying an additional 23 shares during the period. Bollard Group LLC increased its stake in Johnson & Johnson by 0.7% in the second quarter. Bollard Group LLC now owns 3,895 shares of the company’s stock worth $473,000 after buying an additional 27 shares during the period. Armbruster Capital Management Inc. increased its stake in Johnson & Johnson by 0.7% in the second quarter. Armbruster Capital Management Inc. now owns 4,438 shares of the company’s stock worth $538,000 after buying an additional 30 shares during the period. Finally, Amarillo National Bank increased its stake in Johnson & Johnson by 0.6% in the second quarter. Amarillo National Bank now owns 5,496 shares of the company’s stock worth $667,000 after buying an additional 35 shares during the period. 65.32% of the stock is currently owned by institutional investors and hedge funds.
Shares of Johnson & Johnson (NYSE:JNJ) traded down 0.87% during trading on Monday, hitting $117.78. 5,995,981 shares of the stock traded hands. The firm has a market capitalization of $322.23 billion, a price-to-earnings ratio of 21.95 and a beta of 0.61. Johnson & Johnson has a 1-year low of $89.90 and a 1-year high of $126.07. The firm has a 50-day moving average of $119.99 and a 200-day moving average of $116.25.
Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings results on Tuesday, July 19th. The company reported $1.74 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.68 by $0.06. Johnson & Johnson had a net margin of 20.97% and a return on equity of 24.70%. The company earned $18.50 billion during the quarter, compared to the consensus estimate of $17.98 billion. On average, equities analysts forecast that Johnson & Johnson will post $6.69 earnings per share for the current year.
The company also recently declared a quarterly dividend, which was paid on Tuesday, September 6th. Stockholders of record on Tuesday, August 23rd were issued a dividend of $0.80 per share. This represents a $3.20 dividend on an annualized basis and a dividend yield of 2.72%. The ex-dividend date was Friday, August 19th. Johnson & Johnson’s dividend payout ratio (DPR) is presently 60.15%.
A number of equities research analysts recently weighed in on the company. Zacks Investment Research raised Johnson & Johnson from a “hold” rating to a “buy” rating and set a $139.00 target price on the stock in a research report on Friday, August 5th. Deutsche Bank AG restated a “hold” rating and set a $142.00 price target (up previously from $125.00) on shares of Johnson & Johnson in a research note on Thursday, July 21st. Jefferies Group restated a “hold” rating and set a $109.00 price target (up previously from $108.00) on shares of Johnson & Johnson in a research note on Tuesday, June 14th. BMO Capital Markets restated an “outperform” rating and set a $132.00 price target on shares of Johnson & Johnson in a research note on Wednesday, July 20th. Finally, Vetr upgraded shares of Johnson & Johnson from a “sell” rating to a “hold” rating and set a $124.21 price target for the company in a research note on Monday, August 8th. One equities research analyst has rated the stock with a sell rating, thirteen have issued a hold rating and ten have given a buy rating to the company. Johnson & Johnson currently has a consensus rating of “Hold” and a consensus target price of $120.19.
In other news, VP Dominic J. Caruso sold 41,146 shares of the company’s stock in a transaction that occurred on Tuesday, July 26th. The shares were sold at an average price of $125.01, for a total transaction of $5,143,661.46. Following the completion of the sale, the vice president now owns 157,819 shares of the company’s stock, valued at approximately $19,728,953.19. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CAO Ronald A. Kapusta sold 2,935 shares of the company’s stock in a transaction that occurred on Friday, July 22nd. The stock was sold at an average price of $125.01, for a total transaction of $366,904.35. Following the sale, the chief accounting officer now directly owns 28,660 shares of the company’s stock, valued at approximately $3,582,786.60. The disclosure for this sale can be found here. Insiders own 0.11% of the company’s stock.
About Johnson & Johnson
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. The Company’s segments include Consumer, Pharmaceutical and Medical Devices. The Consumer segment includes a range of products used in the baby care, oral care, skin care, over-the-counter pharmaceutical, women’s health and wound care markets.
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.